| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
12,653,000 |
| Market
Cap: |
2.37(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.187 - $0.187 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kiora Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing products for treating disorders of the eye. Co.'s key product in clinical development is the EyeGate Ocular Bandage Gel, a topically applied eye drop formulation of modified hyaluronic acid (HA). HA is a naturally occurring polymer that is used in various physiological processes, including wound healing, hydration, tissue homeostasis, and joint lubrication. Co. modifies the HA through chemical cross-linking, which allows it to adhere to the ocular surface providing protection and lubrication for the treatment of corneal wounds, defects, and epitheliopathies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Manzo Michael P. |
VP of Engineering |
• – – |
2020-03-09 |
4 |
D |
$5.01 |
$651 |
D/D |
(130) |
18,291 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2020-03-09 |
4 |
D |
$5.00 |
$3,560 |
D/D |
(712) |
83,617 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2020-03-09 |
4 |
D |
$5.01 |
$651 |
D/D |
(130) |
26,612 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2020-03-09 |
4 |
D |
$5.00 |
$650 |
D/D |
(130) |
18,268 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2020-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
18,398 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2020-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
84,329 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2020-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
18,421 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2020-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
26,742 |
|
- |
|
| Boyd Steven |
Director |
– • • |
2020-02-10 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
1,815,500 |
2.17 |
- |
|
| Boyd Steven |
Director |
– • • |
2020-02-10 |
4 |
B |
$6.04 |
$72,480 |
D/D |
12,000 |
1,815,500 |
3.92 |
- |
|
| Boyd Steven |
Director |
– • • |
2020-02-06 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
1,803,500 |
2.17 |
- |
|
| Boyd Steven |
Director |
– • • |
2020-02-06 |
4 |
B |
$6.18 |
$67,980 |
D/D |
11,000 |
1,803,500 |
3.92 |
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2020-02-04 |
4 |
D |
$6.00 |
$654 |
D/D |
(109) |
16,742 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2020-02-04 |
4 |
D |
$6.00 |
$654 |
D/D |
(109) |
10,898 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2020-02-04 |
4 |
D |
$6.00 |
$3,504 |
D/D |
(584) |
64,329 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2020-02-04 |
4 |
D |
$6.00 |
$654 |
D/D |
(109) |
10,921 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2020-01-03 |
4 |
D |
$9.52 |
$6,950 |
D/D |
(730) |
64,913 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2020-01-03 |
4 |
D |
$9.52 |
$1,133 |
D/D |
(119) |
16,851 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2020-01-03 |
4 |
D |
$9.52 |
$1,133 |
D/D |
(119) |
11,007 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2020-01-03 |
4 |
D |
$9.52 |
$1,133 |
D/D |
(119) |
11,030 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2019-12-18 |
4 |
D |
$7.46 |
$4,871 |
D/D |
(653) |
65,643 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2019-12-18 |
4 |
D |
$7.46 |
$753 |
D/D |
(101) |
11,126 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2019-12-18 |
4 |
D |
$7.46 |
$753 |
D/D |
(101) |
11,149 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2019-12-18 |
4 |
D |
$7.46 |
$753 |
D/D |
(101) |
16,970 |
|
- |
|
| Goldberg Morton |
Director |
– • – |
2019-12-06 |
4 |
S |
$6.93 |
$13,590 |
D/D |
(1,961) |
0 |
|
- |
|
289 Records found
|
|
Page 5 of 12 |
|
|
